The prognostic difference may be explained by the association of MLH1 promotor methylation cases with a high histologic grade, lymphovascular invasion, larger tumor size, and a higher expression of PD-1 and PD-L1 in peritumoral immune cells. This evidence concerns the gene PDCD1 and neoplasm.